IQVIA Surpasses Q1 2026 Forecasts, Stock Surges

IQVIA Holdings reported Q1 2026 revenue of $4.15 billion, up 8.4% year-over-year (+6.0% at constant currency), beating analyst expectations. Adjusted EPS came in at $2.90, a 7.4% improvement versus the prior-year period. The strong earnings performance drove IQV shares sharply higher on the report date, reflecting investor relief after a period of uncertainty around the company's contract research organization (CRO) backlog.

Following the beat, IQVIA raised its full-year 2026 guidance — now projecting revenue of $17.15–$17.35 billion (+5.2% to +6.4% YoY) and adjusted EPS of $12.65–$12.95. For Q2 2026, management guided adjusted EPS of $2.98–$3.08, signaling continued momentum across its clinical development, real-world evidence, and commercial solutions divisions.

IQVIA's results reflect resilient demand for clinical research services and health data analytics despite macro headwinds facing the broader healthcare sector. The company's diversified business model — spanning decentralized clinical trials, regulatory science, and technology-enabled solutions — continues to attract large pharmaceutical and biotech clients seeking efficiency gains in drug development. Investors will monitor Q2 execution closely, particularly given increasing competition in CRO from rivals including ICON PLC and LabCorp's Fortrea.

Related Stocks

• IQV